Can tedizolid and clindamycin be used together?

Can Tedizolid and Clindamycin Be Combined?

Yes, tedizolid and clindamycin can be safely combined without pharmacodynamic antagonism or synergy, though there is typically no clinical benefit to using them together since both target Gram-positive organisms and combination therapy is rarely indicated for most skin and soft tissue infections.

Pharmacodynamic Compatibility

The FDA label for tedizolid explicitly addresses this combination, stating that in vitro drug combination studies with tedizolid and clindamycin demonstrate neither synergy nor antagonism 1. This means:

• No harmful drug-drug interaction exists between these two agents from a pharmacodynamic perspective 1
• The drugs do not interfere with each other's antibacterial activity 1
• However, they also do not enhance each other's efficacy 1

Clinical Context and Practical Considerations

When Combination Might Be Considered

The IDSA guidelines provide scenarios where clindamycin is recommended for specific Gram-positive infections 2:

• Necrotizing fasciitis with Group A Streptococcus: Clindamycin plus penicillin is specifically recommended because clindamycin suppresses streptococcal toxin and cytokine production 2
• In this scenario, if clindamycin resistance is documented, tedizolid could theoretically serve as an alternative oxazolidinone

Why Combination Is Usually Unnecessary

For most clinical situations, combining these agents offers no advantage:

• Both are bacteriostatic against staphylococci, streptococci, and enterococci 1
• Both target the same organisms: MRSA, MSSA, streptococci, and enterococci 2, 1
• Overlapping spectrum makes dual therapy redundant for typical skin and soft tissue infections 2

Important Caveats

• Clindamycin resistance rates matter: IDSA guidelines recommend clindamycin only when local resistance rates are low (e.g., <10%) 2
• Tedizolid as monotherapy is FDA-approved for acute bacterial skin and skin structure infections and generally does not require combination therapy 1
• In vitro studies with other staphylococcal combinations showed tedizolid was largely indifferent when combined with other agents (80% of interactions), with occasional synergy with rifampicin but potential antagonism with fluoroquinolones 3

Safety Profile When Used Together

If clinical circumstances require both agents:

• No pharmacokinetic interactions are expected based on tedizolid's metabolism profile 1
• Monitor for individual drug toxicities rather than interaction-related adverse effects
• Tedizolid has demonstrated excellent long-term safety without the hematologic toxicity seen with linezolid 4, 5
• Clindamycin's main concerns include C. difficile infection and potential resistance 2

Bottom Line Algorithm

Use tedizolid OR clindamycin as monotherapy for most Gram-positive infections 2, 1. Consider combination only in exceptional circumstances such as:

1. Documented clindamycin-resistant Group A Streptococcus with toxin-mediated disease where you need protein synthesis inhibition (substitute tedizolid for clindamycin) 2, 6
2. Polymicrobial infections requiring clindamycin for anaerobic coverage while tedizolid covers resistant Gram-positives 2

In standard MRSA skin infections, choose one agent based on resistance patterns, cost, and patient-specific factors—combination provides no added benefit 2, 1.